To date, inhibition of the PD-1/PD-L1 pathway by antibodies has become a very powerful therapeutic strategy for patients with various types of cancer and has shown unprecedented clinical responses in advanced tumors (Alsaab et al., 2017). Here, CD274 is linked to cancer.